Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 235,594,941 papers from all fields of science
Search
Sign In
Create Free Account
ponatinib
Known as:
3-(2-(imidazo(1,2-b)pyridazin-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-y-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
, Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)
, Ponatinibum
An orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Ponatinib…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
10 relations
Narrower (2)
AP24534
Iclusig
Broader (4)
Antineoplastic Agents
Imidazoles
Protein Kinase Inhibitors
Pyridazines
NCIt Antineoplastic Agent Terminology
Receptor Tyrosine Kinase Inhibition
ponatinib 45 MG Oral Tablet [Iclusig]
ponatinib hydrochloride
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Ponatinib Before and after Allogeneic Stem Cell Transplantation for Ph+ Acute Lymphoblastic Leukemia or Lymphoid Blast Crisis of Chronic Myelogenous Leukemia: A Single Center Experience
F. Sorà
,
P. Chiusolo
,
L. Laurenti
,
S. Soverini
,
S. Sica
2016
Corpus ID: 79069668
Role of Ponatinib, given as bridge to transplantation or at relapse after aSCT in patients affected by Philadelphia acute…
Expand
2015
2015
Relationship of Line of Therapy to Efficacy for Ponatinib in 3rd-Line Versus 4th-Line Chronic-Phase Chronic Myeloid Leukemia (CML)
M. Levy
,
L. McGarry
,
S. Lustgarten
,
Mo Yang
,
F. Haluska
2015
Corpus ID: 78542528
Background: Chronic-phase chronic myeloid leukemia (CP-CML) patients treated with tyrosine kinase inhibitors (TKIs) can expect to…
Expand
2014
2014
Small Molecule Therapeutics BET Protein Antagonist JQ 1 Is Synergistically Lethal with FLT 3 Tyrosine Kinase Inhibitor ( TKI ) and Overcomes Resistance to FLT 3-TKI in AML Cells Expressing FLT-ITD
W. Fiskus
,
Sunil Sharma
,
+7 authors
K. Bhalla
2014
Corpus ID: 45336226
Recently, treatment with bromodomain and extraterminal protein antagonist (BA) such as JQ1 has been shown to inhibit growth and…
Expand
2014
2014
BCR-ABL Point Mutations and TKI Treatment in CML Patients
S. Kimura
,
T. Ando
,
K. Kojima
2014
Corpus ID: 56329
Most newly diagnosed CML patients in the Chronic Phase (CP), when treated with imatinib, achieve durable responses. However, a…
Expand
2014
2014
Ponatinib circumvents FGF2-driven resistance to imatinib in CML.
Cancer Discovery
2014
Corpus ID: 40305970
FGF2 induces imatinib resistance in CML cells via reactivation of FGFR3-RAS-MAPK signaling.
2014
2014
BCR-ABL1 compound mutations drive ponatinib resistance.
Cancer Discovery
2014
Corpus ID: 22632743
BCR-ABL1 compound mutations harboring T315I are resistant to multiple TKIs, including ponatinib.
2014
2014
Reversing Halt, FDA reauthorizes sale of ponatinib.
Andrew J. Roth
American Journal of Managed Care
2014
Corpus ID: 32583329
2013
2013
As leukemia options grow, drugs jockey to be first-line therapies
E. Dolgin
Nature Network Boston
2013
Corpus ID: 205375491
2012
2012
Ponatinib for chronic myeloid leukemia.
J. Goldman
New England Journal of Medicine
2012
Corpus ID: 205077643
The treatment of patients with chronic myeloid leukemia (CML) must be ranked as one of the great medical success stories of the…
Expand
2011
2011
Preclinical Development Potent Activity of Ponatinib ( AP 24534 ) in Models of FLT 3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies
J. Gozgit
,
M. Wong
,
+9 authors
V. Rivera
2011
Corpus ID: 41525902
Ponatinib (AP24534) is a novel multitargeted kinase inhibitor that potently inhibits native andmutant BCRABL at clinically…
Expand